Resverlogix (RFS) Stock Overview
A late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
RFS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Resverlogix Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.049 |
| 52 Week High | CA$0.16 |
| 52 Week Low | CA$0.028 |
| Beta | 1.05 |
| 1 Month Change | -10.91% |
| 3 Month Change | -4.85% |
| 1 Year Change | 58.06% |
| 3 Year Change | -36.77% |
| 5 Year Change | -90.75% |
| Change since IPO | -97.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| RFS | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.7% | -0.5% | 2.0% |
| 1Y | 58.1% | 17.0% | 1.2% |
Return vs Industry: RFS exceeded the German Biotechs industry which returned 17.2% over the past year.
Return vs Market: RFS exceeded the German Market which returned 2.9% over the past year.
Price Volatility
| RFS volatility | |
|---|---|
| RFS Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: RFS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RFS's weekly volatility has decreased from 19% to 13% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Don McCaffrey | www.resverlogix.com |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd.
Resverlogix Corp. Fundamentals Summary
| RFS fundamental statistics | |
|---|---|
| Market cap | €19.10m |
| Earnings (TTM) | -€5.45m |
| Revenue (TTM) | n/a |
Is RFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RFS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.22m |
| Earnings | -US$6.22m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -97.8% |
How did RFS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/07 06:46 |
| End of Day Share Price | 2026/07/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Resverlogix Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Claude Camiré | Paradigm Capital, Inc. |
| null null | Roth Capital Partners |